On Tuesday, Summit Therapeutics Inc (NASDAQ: SMMT) was 7.00% up from the session before settling in for the closing price of $17.44. A 52-week range for SMMT has been $15.55 – $36.91.
During the last 5-year period, the sales drop of Healthcare Sector giant was -10.52%. When this article was written, the company’s average yearly earnings per share was at -324.58%. With a float of $102.73 million, this company’s outstanding shares have now reached $744.44 million.
Summit Therapeutics Inc (SMMT) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Summit Therapeutics Inc stocks. The insider ownership of Summit Therapeutics Inc is 86.17%, while institutional ownership is 14.07%. The most recent insider transaction that took place on Oct 21 ’25, was worth 9,999,983. In this transaction Director of this company bought 533,617 shares at a rate of $18.74, taking the stock ownership to the 32,057,147 shares. Before that another transaction happened on Oct 21 ’25, when Company’s Co-Chief Executive Officer bought 26,680 for $18.74, making the entire transaction worth $499,983. This insider now owns 76,680 shares in total.
Summit Therapeutics Inc (SMMT) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.06 earnings per share (EPS) during the time that was better than consensus figure (set at -0.06) by -0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -324.58% per share during the next fiscal year.
Summit Therapeutics Inc (NASDAQ: SMMT) Trading Performance Indicators
You can see what Summit Therapeutics Inc (SMMT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.24, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -0.91 in one year’s time.
Technical Analysis of Summit Therapeutics Inc (SMMT)
Looking closely at Summit Therapeutics Inc (NASDAQ: SMMT), its last 5-days average volume was 2.13 million, which is a drop from its year-to-date volume of 2.52 million. As of the previous 9 days, the stock’s Stochastic %D was 43.25%.
During the past 100 days, Summit Therapeutics Inc’s (SMMT) raw stochastic average was set at 21.07%, which indicates a significant decrease from 84.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.61 in the past 14 days, which was lower than the 1.09 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.92, while its 200-day Moving Average is $21.82. However, in the short run, Summit Therapeutics Inc’s stock first resistance to watch stands at $19.29. Second resistance stands at $19.91. The third major resistance level sits at $20.83. If the price goes on to break the first support level at $17.75, it is likely to go to the next support level at $16.83. Now, if the price goes above the second support level, the third support stands at $16.21.
Summit Therapeutics Inc (NASDAQ: SMMT) Key Stats
There are 771,150K outstanding shares of the company, which has a market capitalization of 13.86 billion. As of now, sales total 0 K while income totals -221,320 K. Its latest quarter income was 0 K while its last quarter net income were -231,790 K.
